Get the Stockscreener App
13.31
4.04%
-0.56
After Hours:
13.37
0.06
+0.45%
Intellia Therapeutics Inc stock is traded at $13.31, with a volume of 4.86M.
It is down -4.04% in the last 24 hours and up +1.37% over the past month.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$13.87
Open:
$14.15
24h Volume:
4.86M
Relative Volume:
1.00
Market Cap:
$1.58B
Revenue:
$67.67M
Net Income/Loss:
$-412.69M
P/E Ratio:
-3.4783
EPS:
-3.8266
Net Cash Flow:
$-395.87M
1W Performance:
+0.83%
1M Performance:
+1.37%
6M Performance:
-1.92%
1Y Performance:
+57.70%
1-Day Range:
$13.20
$14.33
1-Week Range:
$11.76
$14.33
52-Week Range:
$6.83
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
13.31 | 1.65B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-11-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-28-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-27-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-27-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying - Barchart.com
Intellia Therapeutics Announces Investor Conference Participation on May 5, 2026 - geneonline.com
Three Intellia fireside chats will stream live through June 3 - Stock Titan
Intellia Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Shareholders of Intellia Therapeutics, Inc. Should Contact Levi - The National Law Review
ARK Invest Increases Stake in Intellia Therapeutics (NTLA) Amid Sector Rotation - GuruFocus
Intellia Therapeutics says its CRISPR-based treatment succeeds in pivotal trial - MSN
Lonvo-z gene-editing therapy lowers HAE attacks by 87% in Phase 3 trial - Angioedema News
Intellia Initiates Rolling BLA Submission For In Vivo CRISPR Therapy In Hereditary Angioedema - marketscreener.com
NTLA stock rises 20% in 3 months: Here's what you should know - MSN
Behavioral Patterns of NTLA and Institutional Flows - Stock Traders Daily
Intellia Therapeutics shares slip despite strong phase 3 data - MSN
NTLA jumps premarket on positive late-stage trial data for gene-editing therapy — retail says buy now before it’s too late - MSN
Intellia Therapeutics, Inc. Sued for Securities Law Violations - GuruFocus
Intellia Therapeutics (NTLA) Sees Major Purchase by ARK Investme - GuruFocus
Cathie Wood’s ARK sells AMD stock, buys Roblox and Intellia - Investing.com
Intellia Therapeutics Prices Public Equity Offering to Fund Pipeline - The Globe and Mail
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
43 new Intellia employees get stock awards worth 208,850 shares - Stock Titan
Intellia Therapeutics prices $180M stock offering at discount - MSN
Intellia Therapeutics | DEF 14A: Definitive information statements - Moomoo
Intellia Therapeutics (NTLA) Is Down 15.1% After Phase 3 lonvo-z Data And $180M Equity RaiseHas The Bull Case Changed? - Yahoo Finance
Intellia Therapeutics | SCHEDULE 13G: Others - Moomoo
Intellia (NASDAQ: NTLA) equity sale boosts cash runway into 2028 - Stock Titan
Intellia Therapeutics (NASDAQ: NTLA) sets 2026 virtual meeting on directors, pay and auditor - Stock Titan
MSN Money - MSN
NTLA Stock Draws Bulls After Phase 3 Gene-Editing Win - StocksToTrade
[ARS] Intellia Therapeutics, Inc. SEC Filing - Stock Titan
Vanguard (NTLA) files Schedule 13G reporting 5.03% ownership (5.95M) - Stock Titan
Intellia Therapeutics | 424B5: Prospectus - Moomoo
NTLA Forecast, Price Target & Analyst Ratings | INTELLIA THERAPEUTICS INC (NASDAQ:NTLA) - ChartMill
ARK Investment Acquires 2.4 Million Shares of Intellia Therapeutics (NTLA) - GuruFocus
$Intellia Therapeutics (NTLA.US)$ Hope u will give me good profit starr from today - Moomoo
Intellia Therapeutics (NASDAQ: NTLA) offers 16.7M shares at $10.75 - Stock Titan
NTLA Stock Slides As $150M Offering Signals Dilution Risk - timothysykes.com
Vanguard Portfolio Management holds 5.3% of Intellia (NASDAQ: NTLA) - Stock Titan
Intellia Therapeutics earnings in focus after gene editing breakthrough By Investing.com - Investing.com South Africa
Intellia Therapeutics earnings in focus after gene editing breakthrough - Investing.com UK
NTLA Stock Pressured As $150M Offering Tests Trader Nerves - StocksToTrade
NTLA Secures $180 Million in Increased Common Stock Offering - GuruFocus
Intellia Therapeutics (NTLA) Launches $180M Public Offering Amid Share Price Drop - GuruFocus
Intellia Therapeutics stock tumbles on discounted offering - Investing.com
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Intellia Therapeutics (NTLA) and Incyte (INCY) - The Globe and Mail
NTLA Stock Slips As $150M Equity Offering Raises Dilution Fears - timothysykes.com
Intellia Files BLA After Lonvo-z Meets Phase 3 Endpoints - CRISPR Medicine News
Intellia Therapeutics stock tumbles on discounted offering By Investing.com - Investing.com India
Intellia Therapeutics stock tumbles on dilutive offering By Investing.com - Investing.com Canada
Intellia Therapeutics stock tumbles on dilutive offering - Investing.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA), Biogen (BIIB) and HCA Healthcare (HCA) - The Globe and Mail
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock - The Manila Times
Gene-editing biotech Intellia prices stock sale for about $180M - Stock Titan
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):